[
    [
        {
            "time": "",
            "original_text": "新药 | 劲方药业KRAS G12C抑制剂GFH925申报临床，安进、诺华、贝达药业等多家企业布局",
            "features": {
                "keywords": [
                    "劲方药业",
                    "KRAS G12C抑制剂",
                    "GFH925",
                    "申报临床",
                    "安进",
                    "诺华",
                    "贝达药业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "新药 | 劲方药业KRAS G12C抑制剂GFH925申报临床，安进、诺华、贝达药业等多家企业布局",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]